We describ e the methodology and rationale behind the delivery of therapeutic medicines to the inner ear. The inner ear has long been impervious to pharmac ologic manipulation. This is most likely the result ofa prote ctive mechanism called the blood-labyrinth barrier, whose function closely resembles that of the blood-brain barrier. This protective barrier impedes the clinician's ability to treat inner ear diseases with systemically administered medications. Since 1935, otolaryngologists have attempted to manipulate the inner ear with transtympanically injected medicines. Success has varied widely, but medicinal ablation of vestibularfunction can be achieved in this manner. Unfortunately, the auditory system is also at great risk from any medicine that is delivered to the inner ear via the middle ear. Over the past 10 years, significant improv ements in drug delivery have allowed f or more "titratable'' treatment, which has reduced (but not eliminated) the risk of permanent hearing loss. In this article, we discuss both novel and time-tested methods of delivering medicines to the inner ear. We also review the classes of medications that alter inner ear function and the attendant risks of such treatments.
Introduction
The ability to locally or directly treat inner ear disea ses has eluded the scientist and clinician for years . It is well known that the inner ear is isolated, physically and ana - tomically, from the rest of the body's systems. Therefore, although systemically admi nistered medications used to treat otologic abnormalities might have a desired effec t on the inner ear, their application can be limited by potentially adverse effects on the inner ear. Such limitations have been seen in the use of diuretics for Meniere's disease, anxio lytics for tinnitus, and stero ids for autoimmune inner ear disease. For example, diuretics are used to reduce the overall fluid volume to the inner ear as part of the management of Meniere's syndrome. However, their primary effect is a reduction of fluid systemically, with probably only a very slight fluid reduction in the inner ear. One ofthe side effects of some diuretics is that they lower potassium levels. It would be much better and perhaps more target-specific if we had a diuretic that worked only on the inner ear without causing systemic side effects. When given systemically, some medications have a profound effect on the inner ear. For example, aspirin in high doses causes tinnitus, and certain aminoglycosides, when given systemically, pas's into the inner ear and can cause permanent balance and auditory disturbances.Likewise, the systemic use of cisp latin for its antitumor activity can cause significant hearing loss . Therefore, it would be most beneficial if we could deve lop means to use novel medic ines and novel delivery techniques to both treat the labyrinth and protect the inner ear from harm . Perhaps if the ear could be treated with a protective agent (e.g ., methionine), hearing could be spared without reducing or eliminating the anticancer effects of a chemotherapeutic regimen . A poignant example can be found in China , where the leading cause of hearing loss (60% of all cases) is ototoxicity from aminoglycosides that are used routinely for the treatment of bacte rial infections.' Sha and Schacht have shown that iron chelators and aspirin can ameliorate the ototoxic effec ts of the aminoglycosides withou t red ucing their antibacterial properties. ' Perturbations in oxygenation , blood supp ly, nutrient delivery, and waste elimination in the inner ear can all have deleterious effects on otologic function. Interest- ENT l~~HOOD fIll, LABORATORIES · ingly, even minute changes in inner ear dynamics, regulatory mechanisms, and homeostasis can cause tinnitus, a severe balance disturbance, and/or a complete hearing loss. Tinnitus alone affects 90 million people worldwide, hearing loss affects more than 30 million Americans, and more than 50% of patients older than 65 years have experienced some difficulty with balance. ' Although the theme of this article might suggest that the delivery of medicines via a local route to the inner ear to treat specific otopathologies is new, this is not the case. There is a significant history of such delivery that dates back to 1935, when Barany reported his treatment of Meniere's disease patients with middle ear delivery of lidocaine.' Later, Schuknecht reported his use of streptomycin,' and Sakata et al published their results with steroids." Many others have reported direct transtympanic treatment of the inner ear for a number of different otologic disorders.v"
The rationale for treating inner ear disorders directly seems to be logical. For years, ophthalmologists had a significant advantage in the management and treatment of ocular diseases merely by applying appropriate drops to the eye . But in light of the presence of the blood-labyrinth barrier, the nonselectivity of some drugs (systemic drugs typically do not go directly to the inner ear), and the tympanic membrane, otolaryngologists cannot always use the particular medications we would prefer to use.
Many delivery techniques are available to treat the inner ear. The three procedures that are most often used all involve trans tympanic drug delivery; the three tools used are a tuberculin syringe and a 27-gauge or smaller-gauge needle , the round window microcatheter (Round Window m-Cath ; Durect Corp.; Cupertino, Calif.), and the Silverstein MicroWick (Micromedics; Eagan, Minn .).
Prior to undertaking a specific intervention, of course, it is critical to understand the pathophysiology of the particular disease that is being treated. The mechanisms of many common otologic disorders, while understood in part, have not been completely elucidated. Specifically, Meniere's disease has long been thought to occur as a result of endolymphatic hydrops, but the true cause of this pathology is still open to speculation. While we have reasonable medical and surgical options for the treatment of the vertigo associated with Meniere's disease, the efficacy of our choices for the management of associated hearing loss, aural fullness, and tinnitus pales in comparison. These latter symptoms are often just as disconcerting to the patient as is the vertigo .
Some scientific evidence and a moderate amount of clinical and anecdotal evidence support the use of steroids applied directly to the middle ear cavity and round window membrane for the management of hearing loss, aural fullness, and perhaps tinnitus in selected patients.6.8.1 3-16.21-25 Exploratory tympanotomy allows us to directly perfuse 278 the inner ear as well as directly explore the round window membrane. It is important that adhesions surrounding the round window membrane niche are removed to ensure that fluid transfer through the membrane is not impeded. Doing so will eliminate one potential cause of treatment failure. Even so, this idea is certainly controversial, particularly with respect to the use of trans tympanic gentamicin without exploring the middle ear to remove round window adhesions. Transtympanic gentamicin appears to alleviate vertigo in as many as 85% of patients.v" Could the treatment failures be attributable to the fact that medicine was eliminated too quickly via the eustachian tube? Or could they be attributable to a lack of direct access to the round window membrane as a result of preexisting adhesions? Clearly, many questions remain to be answered, but some of the variability in outcomes could be controlled if clinicians and investigators had more standardized treatment paradigms.
Many otologic disorders might respond to direct pharmacologic manipulation of the labyrinth. They include (but are not limited to) sudden sensorineural hearing loss, noise-induced hearing loss, ischemia-induced hearing loss, virus-induced hearing loss, autoimmune inner ear disease , tinnitus of the peripheral type, congenital or acquired hearing loss (using gene vectors), and balance disturbances that are peripheral in origin.
Many medications can be used to treat the inner ear, and they have been discussed extensively in several articles . The most frequently used intratympanic medications are gentamicin and steroids. Less-used options are antioxidants, growth factors, antivirals, diuretics, vasodilators, antisense oligonucleotide agents, gene vectors, and others. 6, 8, [13] [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] [25] [35] [36] [37] [38] [39] In this article, we provide a general discussion of some of the more commonly used medications as well as some novel compounds that might have a role in the pharmacologic manipulation of the inner ear. We also provide a rationale for their use.
Antibiotics
The aminoglycoside antibiotics are routinely used to treat aerobic gram-negative .bacterial infections. As a result , their ototoxic side effects have been well documented in the literature and in everyday practice.P:" In attempts to treat Meniere's disease, otolaryngologists have used the aminoglycosides to partially ablate vestibular function for vertigo relief while attempting to maintain cochlear function . Beginning in 1957, the use of streptomycin administered directly to the middle ear resulted in an overall alleviation of vertigo, but hearing loss was evident in all patients. 5 Subsequent studies with gentamicin showed significant improvements in relieving vertigo (>84 %) and much less treatment-related hearing loss «58%), presumably because gentamicin differentially destroys the In clinical trials, commonly reported adverse events w ith RHINOCORT AQUA versus vehicle placebo were epistaxis (8% vs 5 %), pha ryngitis (4% vs 3%), bronchospasm (2% vs 1%), cough ing (2% vs < 1%), and nasal irritation (2% vs < 1%). The overall incidence of adverse events with RHINOCORT AQUA was similar to that observed with vehicle placebo. Please see brief summary of full Prescribing Information on adjacent page. AstraZenecaÃ similaradverse event profilewas observed in the subgroupof pediatric patients 6 to 12years ofage. Two to threepercent (2-3%)ofpatients inclinical trialsdiscontinuedbecauseof adverseevents. Systemiccort icosteroid side effectswerenot re ported during controlledclinicalstudies with RHINOCORT AQUA Nasal Spray. If recommendeddosesareexceeded, however, or if indivi dualsare part icularly sensitive, symptoms of hypercorticism, ie, Cushing's Syndrome, could occur. Rareadverse events reported from post-marketing experience include: nasal septum perforation, pharynx disorders (throat irritation, throat pain, swollen throat, burning throat, and itchy throat), angioedema, anosmia, and palpitations. Cases ofgrowt h suppression have been reported for intranasal corticosteroids including RHINOCORTAQUA Nasal Spray (see PRECAUTI ONS, PediatricUse). DOSAGE AND ADMINISTRATION Therecommended starting dose for adults and children6years ofage and older is64 mcg per day administered as one sprayper nostril ofRHINOCORTAQUA Nasal Spray 32mcg once daily. Themaximum recommendeddose foradults(12years ofage and older) is 256 mcg per day admini stered asfour spraysper nostril once dailyofRHINOCORTAQUA NasalSpray 32mcg and the maximum recommended doseforpediatr icpati ents (<12 yearsofage) is128mcg perday administered as iwe spraysper nostriloncedaily ofRHINOCORTAQUA Nasal Spray32mcg (seeHO WSUPPLIED).IndividualizationofDosage:It isal waysdesirable totitrate an individual patient totheminimum eff ectivedosetoreduce the possibilityofside eff ects. HOW SUPPLIED: RHINOCORT AQUA Nasal Spray 32 mcg is avai labl e in a green coat ed glass bottlewit h a met er ed-dose pump spray and a green protection cap. RHINOCORT AQUA Nasal Spray 32 mcg provides t20metered spraysafter ini tialpriming; net fill wei ght 8.6g. TheRH INOCORTAQUA Nasal Spray 32mcgbottle has been filled wi th an excess to accommodate the priming acti vity. The bottle should be discarded after 120 sprays following ini tial priming, since the amount of budesonide delivered per spray thereaft er may be substantially less thanthelabeleddose. Eachspraydeliver s32mcgof budesonidetothe patient. 808201-04 Rev. 10101 205359 Alltrademarksare thepropertyoftheAstraZenecagroup ©AstraZeneca2002 MEAN on rhin it is mended daily intranasal dosein adults and children ona mcg/m' basis). 8udesonidewas not mutageni c or clastogeni c insixdifferent test systems: Ames, Salmonella/microsomepl at etest, mouse micronucleus test, mouselymphomatest, chromosome aberrationtestinhuman lymphocytes. sex-linkedrecessi velelhaltest in Or osopl1ifa melanogaster, and DNA repair analysis in rat hematocyt e cullure. In rats, budesonide caused a decrease in prenat al viability andviability of the pups at bi rthand duringlactation, along witha decrease in maternal body-weight gai n, atsubcutaneous doses of 20mcg/kg and above(less than the maximum recommended dailyintranasal doseinadults onamcg/m' basi s). No sucheffectswerenoted at 5mcglkg(less than the maximum recommended daily intranasal dose in adult s on a mcg/m' basis). Pregnancy: Teratogenic Effects: PregnancyCategoryC: Budesonidewasteratogenic and embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pupweights, and skeletal abnormalities at subcutaneous doses of 25mcglkg in rabbitsand500 mcglkginrats (approximately 2and16timesthemaximum recommended dailyintranasal dose inadul ts on amcg/m' basis). Inanother study inrats, no teratogenicor embryocidal effectswere seen at inhalation doses up to 250mcg/kg (approxi mately 8 times the maximum recommended daily intranasal dose in adults on a mcg/m' basis). There areno adequateand well-controlled studies in pregnant women. RH INOCORT AQUA Nasal Spray should be used duringpregnancy only if the potential benefit justifies the .potential risk to thefetus. Experiencewi th oral corticosteroidssi nce their introduction in pharmacol ogic, as opposed to physiologic, doses suggests that rodents are more prone to teratogeniceffects from corticosteroidsthan humans. In addition, because ther e is a natural increase in corticosteroid producti on during pregnancy, mostwomenI' lill requirea lower exogenous corticosteroi d doseand many will not need corticosteroid treatment during pregnancy. Nonteratogenic E/lects: Hypoadrenalism may occur in infants born of mothers receivi ng corticosteroids during pregnancy. Such inf antsshould be carefully observed. Nursing Mothers: It is not known whether budesonide isexcreted in human mil k. Because other corticosteroids are excreted inhuman milk, cautionshoul d beexercisedwhen RHINOCORT AQUANasalSprayisadministeredto nursing women.Pediatric Use: Safet y and eff ectiveness in pediatric patients below6years of age have not been established. Controlled clinical studies haveshownthat intranasal corticosteroids maycause areduction inqrowth velocityinpediat ric patients. This eff ect hasbeen observed inthe absence of laboratory evidence of hypothal amic-pituit ary-adrenal (HPA) axis suppression, suggesting that grol'nhvelocity is a more sensiti ve indicatorofsystemiccorticosteroidexposure inpediatricpati entsthansomecommonlyusedtests ofHPA axis function. Thelong-term effectsof thi s reductioningrowth velocity associated withintranasal corticosteroids, includingthe impact on final adult heig ht, areunknown ,Thepotential for"catchup" growth following discontinuati on of treatment withintranasal corticosteroidshasnot beenadequatelystudied,Thegrowth of pediatric patientsrecei vi ng intranasalcorticosteroids, including RH INOCORT AQUANasal Spray, should bemonitored routinely(eg. viastadiometry). Thepotenti algrowth effectsof prol onged treatment shouldbeweighedagainst clinical benefits obtained andtheavailability of safeand effective noncorticoster oid treatment alternatives. To minimize thesystemic effects of intranasal corticosteroids, including RHINOCORT AQUA NasalSpray, each pati ent shouldbe titrat edtothelowest dose thateffectivelycontrol shis/her symptoms.Geriatric Use: Of the 2,461 patients in clinicalstudies of RHINOCORT AQUA Nasal Spray, 5% were 60years ofageand over . No overalldiff erences in safety or effectiveness wereobserved between these subjectsand younger subjects, except foranadverseevent reportingfrequency ofepistaxiswhi chincreased withage. Further, other reported clini calexperiencehasnot identifiedany otherdi fferencesinresponsesbet ween el derly and younger pati ents, butgreater sensitivity ofsome older individual s cannot be ruled out. ADVERSE REACTlON5 Theincidenceofcommon adverse reactions is based upon two U.S. and fivenon-U.S. controlledclinical trialsin 1,526 patients 11 10femalesand 239 malesless than 18yearsofage, and635 females and542 males 18years ofageand older]treated with RHINOCORTAQUA Nasal Sprayatdosesupto 400mcg once daily for 3-6 weeks.Thetablebel owdescribes adverseevents occurringatan incidenceof 2% or greaterandmorecommonamong RHINOCORT AQUA Nasal Spray-treat ed patients than inpl acebo-t reated patients incont rolled clinical trials. Theoverallincidence ofadverse eventswas similar betweenRHINOCQRT AQUAandplacebo For Intranasal UseOnly.
RHI
BRIEF SUMMARY INDICATIONS AND USAGE RHINOCORTAOUA Nasal Spray is indicated for the management of nasal symptomsof seasonal or perennial allergic rhinitis inadultsandchildrensixyears ofage and older. CONTRAINDICA TI ONSHypersensi tivityto any of theingredients in thi s preparation contraindicates the useof RHINOCORT AOUA Nasal Spray. WARNINGSThereplacement ofasystemic corticosteroid\· ,ithatopical corticoster oidcan beaccompanied by signs of adrenal insufficiency, and in addition some patients may experience symptoms atcorticosteroid withdrawal, eg, joi nt and/or muscular pain, lassitude, and depression. Patient s previously treated for prolonged periodswith systemiccorticosteroids and transferred totopicalcorticosteroidsshouldbecarefullymonitoredfor acuteadrenal insufficiencyin response tostress. In those patients who have asthma orother clinical conditions requiring long-termsystemiccorticosteroidtreatment, too rapidadecrease insystemic corticosteroidsmaycause asevere exacerbation of their symptoms. Patients wh oare ondrugswhi chsuppresstheimmune system aremore susceptibletoinfections thanhealthy individuals.Chickenpoxandmeasles, forexample,canhave amoreserious oreven fat al courseinnon-immune childrenoradul tson immunosuppressant doses ofcorticost eroids. insuch children oradults who havenot had these diseases, particular care should betaken toavoidexposure. Howthe dose, route, and durationofcorticosteroidadministration affects therisk ofdeveloping adisseminated infection is not known. Thecontribution oftheunderlying disease and/orprior corticosteroidtreatment tothe risk isalso notknown. If exposed tochicken pox, prophylaxis withvaricellazosterimmune globulin(VZ IG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (Seethe respective package inserts forcompleteVZ IG and IGprescribi ng informat ion). If chicken poxdevelops, treatment wi thantiviral agents may be considered. PRECAUTIONS: General: Intranasal corticosteroids may cause a reduction in growth velocity when administer ed to pediatric patients (see PRECAUTIONS, Pediatric Use). Rarely, immediate and/or delayed hypersensiti vity reactions may occur after the intranasal admi nistration of budesonide. Rare instan ces of wheezing, nasal septum perforation, and increased intraocular pressure have been reported followi ng the intranasal application of corticosteroids, includi ng budesonide. Although systemic effects havebeen mi nimal wi th recommended doses of RHINOCORT AQUA Nasai Spray, any such effect is dose dependent. Therefore, larger than recommended doses ofRHI NOCORT AOUA Nasal Spray should beavoidedandtheminimal effectivedose forthepatient shoul dbeused (seeDOSAGEAND ADM INI STRATION infullPr escribingInformation). When used at largerdoses, systemic corticosteroid effects such as hypercorticism and adre nal suppression may appear, If such changes occur, the dosageof RHINOCORT AOUA Nasal Spray should be discontinued slowly, consistent with accepted procedures for disconti nuing oral corticosteroid therapy. In clinical studies with budesonideadministered intr anasally,thedevel opment of localized infectionsof the noseand pharynx with Candidaalb icans has occurred onl yrarely. Whensuch aninfectiondevelops, it mayrequiretreatmentwi th appropriate local or systemic therapy and discontinuation of treatmentwith RHINOCQRT AQUANasal Spray. Patientsusing RHINOCORTAQUANasal Spray over several monthsor longer shouldbeexamined periodically for evidence of Candidainfection or other signs ofadverse eff ects on the nasal mucosa. RHINOCORT AQUA NasalSpray should beused wi th caution, if at all , in patients wi thactive or quiescent tuber culous infection, untreated fungal, bacterial , or systemic viral infections, or ocular herpes simplex. Because of the inhi bitory effect of corticosteroidson wound healing, patient s who have experienced recentnasal septal ul cers, nasal sur gery, ornasal traumashould notuseanasal corticosteroiduntil healing hasoccurred. Hepaticdysfunction influences the pharmacokinetics ofbudesonide, similar to theeffect onother corticosteroids, witha reduced eliminati on rate and increased systemic availability (see CLINICAL PHARMACOLOGY section of full Pr escri bing Information). Information for Patients: Patients being treated with RHI NOCORT AQUA Nasal Spray should recei ve the followi ng information and instructions. Pati ents who are on immunosuppressant doses of corticosteroids shoul d be warned to avoid exposureto chicken pox or measl es and, if exposed, to obt ainmedical advice. Patients shoulduse RHINOCORT AQUANasalSprayat regular intervals sinceitseffectiveness depends on its regular use (see DOSAGE AND ADMIN ISTRATION). An improvement in nasal symptoms may benoted in patients wi thin 10 hoursof first using RHINOCORT AQUA NasalSpray. This time to onset is supported by an environmental exposure unit study in seasonal allergic rhinitis patients which demonstrated that RHINOCORTAQUA Nasal Spray led toastatisticallysignificant improvement innasal symptomscom paredtoplaceboby10hours. Furthersupport comes from aclinical study ofpatientswithperennial al lergic rhinitis which demonst rated a statistically sig nificant improvement in nasal symptoms for bot h RHINOCORTAQUA Nasal Spray and for the active comparator (mometasone furoate) comparedtoplaceboby 8 hours. Onset wasalso assessed inthisstudywithpeaknasalinspiratoryftowrat eand this endpoint failedto show efficacy foreit heractivetreat ment. Although statistically significant improvements in nasal symptoms compared toplacebo werenoted within 8-10hours inthesestudies, about onehalf to two thirds of the ultimateclinical improvement with RHINOCORTAQUA Nasal Spray occurs over thefirst 1-2 days,and maximum benefitmay not beachi eved until approximatel y 2 weeksafter initiation of treatment. Initialassessment for responseshould bemade during this time frame and periodicall y until thepatient's symptoms are stabilized. Thepatientshoul dtakethemedication as directed and shouldnotexceedtheprescribed dosage. Thepatient should contact the physician if symptoms do not improve aft er two weeks, or if the condition worsens. Patientswhoexperience recurrentepisodesofepistaxis(nosebleeds)or nasalseptumdi scomfortwhi letaking this medicati onshould contact their physician. For properuse of thi s unitand to attai n maximum improvement, the pat ient shoul d read and follow the accompanying pati ent instructions carefully. It is important to shake thebottlewell before each use. TheRHINOCORT AQUA NasalSpray 32 mcgbottlehas been filled with an excess to accommodate the primingactivity. The bottle shouldbediscarded after 120spraysfoll owing initial priming, sincetheamount of budesonidedelivered per spray thereaftermay besubstantially less than the label ed dose. 00 not transferanyremainingsuspensi on toanother bottle. Drug Interactions: Themain routeof metabol ism of budesonide,aswell asother corticosteroids, isviacytochromeP4503A(CYP3A). After oraladministrat ion ofketoconazole,apotent inhibitorof cytochrome P450 3A, themean plasma concentration of orally administered budesonide increased by more than seven-fold. Concomitant administration of other known inhibitors ofCYP3A (eg, itraconazole, clarithromycin, erythromyci n, etc.)may inhi bit themetabolism of, and increase the systemic exposure to, budesonide (see WARN INGS and PRECAUTIONS, General). Omeprazol e, an inhibi tor of cytochrom e P450 2C19, did not have effects on the pharmacokinet ics of oral budesonlde, while cimetidi ne, pri maril y an inhibitor of cytochrome P450 l A2, caused a slight decrease in budesonideclearance andcorrespondingincreaseinitsoral bioavailability. Carcinogenesis, Mutagenesis, Impairment of Fertility: In a two-year study in Sprague-Dawley rats, budesonide caused a stat istically significant increasein theincidenceof gliomasinthe mal eratsreceivinganoral doseof50mcg/kg (approximatel y twi cethe maximum recommendeddai ly infr anasal doseinadultsandchildren on amcg/m' basis). No tumorigenicity was seen in maleandfemale rats atrespectiveoral doses up to25 and50mcg/kg (approximat ely equaltoand two times the maximum recommended daily intranasaldoseinadul ts and children on a mcg/m' basis, respecti vely). In two addi tional two-year studies in mal e Fischer and Sprague-Dawl ey rats, budesonide caused no gliomasat an oral dose of 50 mcg/kg (approximately twi ce the maximum recommended daily intr anasal dose in adulls and children on a mcg/m' basi s). However, in male Sprague-Dawley rats, budesonide caused astatisticallysignificant increase intheincid enceofhepat ocellular tumors atan oral dose of50mcg/kg (approximatelytwice the maxi mum recommendeddai ly intranasaldose inadults andchildren on a mcg/m' basis). The concu rrenl ref erence corticosteroids (prednisolone and triamcinolone acetonide) in thesetwo studies showed simi lar findings. Ina91-week stud y in mice, budesonide caused no treatment-rel at edcarcinogenicityatoral dosesupto200 mcg/kg (approximatel y3timesthemaximumrecom-MEAN ON RHINITIS, GENTLE ON THE NOS E'M RHINOCORT~~; :Ã nUA' " (budesonide) RW R~32 m c g endolymph-secreting dark cells rather than the cochlear hair cells involved in hearing. administration of gentamicin to optimize the control of vertigo and minimize hearing loss in patients with Meniere's disease has proved to be fairly successful.
Many suggested methods and treatment protocols have been described. Protocols that limit the amount and rate of administration have proved to be the most successful. In 1999, Minor wrote that the best time to discontinue treatment is when spontaneous nystagmus, head-shaking nystagmus, or head-thrust signs are present; vertigo was controlled in 91% of patients, and profound hearing loss occurred in only 3%.32A year later , Kaplan et al reported that intratympanic administration of gentamicin resulted in complete control of vertigo in 84.4% of patients and substantial control in another 9.0 %.34At the 2-year followup, hearing had improved in one-fourth of patients and worsened in one-fourth; the remaining half were unchanged. Thomsen et al delivered gentamicin to the inner ear via a round window microcatheter and found that vertigo was controlled in 81% of patients; however, 22% of patients experienced significant hearing loss, possibly related to the flow rate." Finally, Hoffer et al achieved vertigo control rates of90% without hearing loss in more than 40 patients with Meniere's disease who were treated via the round window membrane niche microcatheter delivery technique."
Corticosteroids
Corticosteroids are commonly used in the management of several inner ear disorders, including sudden sensorineural hearing loss from idiopathic, vascular, viral , or traumatic causes; Meniere's syndrome and disease; autoimmune inner ear disease; and certain vestibulopathies. The activity of steroids varies widely , but these agents primarily affect carbohydrate, lipid, and protein metabolism by interacting with receptors in target tissues that affect the expression of regulatory genes .
Some authors have suggested that steroids might be harmful to the inner ear4 5 .46and other tissues. " In view of these reports and the fact that many clinicians were finding that steroids had some beneficial effects, the lead author's (M.D.S.) laboratory initiated an animal study to investigate the effects of transtympanic steroids on cochlear blood flow , auditory threshold sensitivity, and histology. " We transtympanically injected both dexamethasone and methylprednisolone once a week for 8 consecutive weeks. A separate group of animals was used to assess changes in cochlear blood flow. We found a statistically significant 29% increase in cochlear blood flow within 30 seconds of steroid application to the round window membrane. No change from baseline auditory thresholds was observed, and no difference was seen between treated ears and opposite ears injected with Volume 82, Number 4 saline . Furthermore, no histologic differences were observed between the treatment and control ears.
Typically, the administration of steroids for inner ear disorders has been undertaken via the systemic route . However, in view of the blood-labyrinth barrier ." :" there is a valid concern that adequate inner ear drug levels might not be achieved through this method. Studies have demonstrated that different administration routes result in a significant degree of inconsistency in inner ear steroid levels. For example, delivery via the middle ear cavity route has been reported to result in significantly higher perilymphatic drug levels than does delivery via other routes ."
Even though steroids are a valid therapeutic option for several inner ear disorders, their use is controversial because there have been several anecdotal reports that patients lost additional hearing following the delivery of steroids by catheter. Questions surrounding this issue are numerous, and consideration should be given to the possibility that this additional hearing loss might have been secondary to the progression of the disease itself, to the actions of carrier molecules in the steroid preparation, to infection (bacterial or viral) , to trauma to the round window causing a fistula , and even to the side effects of anesthesia. In general, additional harm is not likely, but patients certainly need to be warned of all potential adverse side effects that can result from the direct delivery of steroids to the middle ear and round window . In 2000, Shea and Ge reported that 35 of 50 ears (70.0 %) that had intractable tinnitus achieved relief within I month of treatment with lidocaine, dexamethasone, and hyaluronidase perfusion of the round window membrane niche in addition to intravenous lidocaine." Relief was maintained in 20 of26 ears (76.9 %) that were tested at 3 months and in 10 ofl2 (83.3%) that were tested at I year. However, these results were met with some skepticism because Shea and Ge also used conventional oral antidepressant medications and provided counseling, which might have had an effect on their findings-that is, we cannot be certain which of the interventions led to the improvement. Additional studies of lidocaine and combined lidocaine/dexamethasone/hyaluronidase are warranted.
Lidocaine and dexamethasone combination

Neuroprotection and glutamate antagonists
Neuroprotection is a process by which neuronal function is shielded from injury oris restored following injury . The two major causes of neuronal injury are ischemia (induced by trauma , hemorrhage, etc.) and neurodegenerative disease. In the inner ear, neuronal injury manifests as hearing loss, vertigo, and tinnitus.
Ischemia in the central and peripheral nervous systems damages neurons in several ways. The oxidative stress that is associated with ischemia produces a variety of damaging reactive oxygen species (ROS), which include hydrogen peroxide, the superoxide anion, and the hydroxyl radical .v" The accumulation of ROS promotes the expression of intercellular adhesion molecules and subsequent neutrophil-endothelial cell adhesion. 58 . 62 A cascade of inflammatory events ensues, which ultimately results in edema, vascular insufficiency, and cell death. 63.65 The reduction of intracellular energy and neuronal depolarization that accompanies ischemia also disrupts calcium homeostasis. The accumulation of intracellular calcium leads to dendritic and cellular edema and ultimately neuronal death ." Furthermore, neuronal depolarization leads to an accumulation of extracellular glutamate (a major excitatory neurotransmitter in the central nervous system and inner ear). Excess glutamate release from depolarized presynaptic neurons, together with a diminution in the uptake mechanisms of glia 'and neurons, results in increases in synaptic glutamate and pathologic stimulation of Nmethyl-D-aspartate (NMDA) receptors.t':" Excessive stimulation of glutamate receptors leads to neuronal injury (i.e., glutamate neuroexcitotoxicity) by either direct or indirect activation of receptors on the postsynaptic neuron /" This leads to an opening of gated channels that allows an influx of sodium, potassium, and calcium. This alteration in intracellular ion concentrations exacerbates dendritic and cellular edema and hastens neuronal death. A breakdown in calcium homeostasis, excessive glutamate activation, oxidative stress, and free-radical production also play significant roles in the age-associated neuropathologic processes that lead to neuronal death.'?"
Inner ear ischemia can be caused by exposure to intense noise. Studies using intravital microscopy , laser Doppler flowmetry, and microcast techniques have demonstrated reduced cochlear blood flow , decreased red blood cell velocity , capillary constriction, and increased vascular permeability during noise exposure .P:" The role of ROS in promoting cellular death in the inner ear and the protective effects of antioxidants and ROS scavengers in attenuating ischemia/reperfusion-induced and noiseinduced cochlear damage have been substantiated in many animal studies.53.55.79
Studies have indicated that glutamate excitotoxicity occurs in the cochlea under pathologic conditions, such as 280 noise trauma and ischernia.w" At least three receptor types are generally ,accepted as being responsible for glutamate excitotoxicity-those selectively activated by NMDA, quisqualate, and kainate. The latter two are non-NMDA receptors . Excitotoxicity appears to be primarily dependent on NMDA and kainate receptor activation. P"
Experimental work has demonstrated that monosodium L-glutamate administered to neonatal rats is toxic to the auditory system and produces a high-frequency hearing loss." The primary peripheral target appears to be the neurons in the spiral ganglion. The lead author's laboratory studied the effects of a broad-spectrum glutamate receptor antagonist, kynurenic acid (KYNA), on glutamate-and noise-induced trauma in guinea pigs ." KYNA is a tryptophan metabolite that has selective activity against NMDA, quisqualate, and kainate receptors in the central nervous system. 81 . 88 , 89 We obtained baseline levels of compound action potentials and cochlear microphonic thresholds in the guinea pigs, and then randomly assigned them to one of three groups :
-Group I received a vehicle control (1.5 M of sodium chloride) applied to the round window membrane, followed by 110 dB of wide-band noise for 90 minutes .
-Group II received 5 mM of KYNA , followed by the same noise exposure.
-Group III received 5 mM of KYNA without noise.
We then measured postdrug and postnoise compound action potentials and cochlear microphonic thresholds. We found that noise exposure caused a moderate and temporary threshold shift of 30 to 40 dB across the frequencies tested (3, 6, 9, 12 , and 18 kHz); the highest temporary threshold shift (40 dB) occurred at 9 kHz . Animals that received KYNA prior to noise exposure (group II) demonstrated significant protection against noise-induced damage, as reflected by their minimal temporary threshold shift (range: 5.4 to 8.4 dB) at 3, 6, 9, 12, and 18 kHz (p<O .OO 1). Animals that received KYNA without noise (group III) experienced no change in hearing thresholds. These findings suggest that antagonizing non-NMDA glutamate receptors attenuates a noiseinduced temporary threshold shift. These data further support the idea that glutamate excitotoxicity might play a direct role in the generation of acoustic trauma and an indirect role in the production of tinnitus."
The hypothesis that subjective tinnitus is primarily caused by glutamate excitotoxicity at the synapses between inner hair cells and their afferents in the cochlea has been confirmed.?? Furthermore, the ionotropic glutamate receptors-NMDA and alpha-amino 
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glutamate has been found to function as the fast excitatory neurotransmitter in these synapses."
Using micro-iontophoretic techniques, several authors have demonstrated that glutamate antagonists can protect the afferent neuro ns of the inner hair cells fro m neuroexcitotoxicity." :"
These studies have prepared the landscape for further effor ts to assess the ability of specific glutamate antagonists and NMD A channel blockers to protect against noise-induced hearin g loss and to serve as a possible treatment for periph eral tinnitus. Three such drugs under investigation are mem antine, caroverine, and magnesium.
Memantine . Memantin e ( l -amino-3, 5-dimethyladamantane) is a low-affinit y, noncompetitive NMD A receptor blocker.v" It has been used in Europe for more than 10 years for the treatment of Parkin son ' s disease" and dementia.P"" Several authors have noted its protective effect against glutamate neuroexcitotoxicity and hypox ia. 101 -105 More recently, studies have demonstrated memantine' s selective NMDA antagonism in the mammalian cochlea. 92 • I06 Additionally, Oestreicher et al proposed the use of glutamate antagonists such as memantine in treating inner ear disorders and reco mme nded that they be delivered locally to the cochlea in order to maintain an effective thera peutic drug level and avoid systemic side effects. 106 The safety and tolerability of meman tine have been clearly demonstrated throughout its use in treating neurologic disorders in Germany. 107, 108 No serious treatmentrelated adverse effects have been recognized . In several double-blind, pla cebo -contr olled trials of memantine as a treatment for prim ary, vascul ar, and Alzheimer' s-related dementia s, only mild and transient side effe cts were encountered. 98 ,100,109,11O Caroverin e. Caroverin e, a quinoxalin e derivative, acts as a competitive AMPA antagoni st, and at higher concentrations it noncomp etitively blocks NMDA receptors at the glycine site in the cochlea.!" The neuroprotective effec ts of caroverine were confir med in a study by Ehrenberger and Felix, who demo nstrated that caro verine can depress the activity of glutamate recep tors in the cochleae of guinea pigs." Caroverine is currently available in some countries (e.g., Austria ) as a spas molytic drug. Its safety and tolerability have been clearly demonstrated in clinica l studie s of alco hol withdrawal syndrome and hypoxia.i' v' !'
The efficacy of caroverine for the treatme nt of tinn itus was demonstrated in a single-blind, placebo-con trolled clinical study by Denk et al." They found that approximately 63% of patient s who were treated with intravenous caroverine repor ted a significant impro vement immed iately following infu sion ; the effec t was still present after I week in 48% of these patients, Although no severe 2124070 (1 0-01) 0404-0H 001
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ENT-Ear, Nose & Thr oa t Journal · Ap ril 2003 adverse effects were identified, a few patients did experience mild and transient side effects, which included a bad taste, vertigo, headache, a "hot head" sensation, and additional noise. However, Saletu et al reported that caroverine might not have any therapeutic effect on tinnitus beyond that seen with placebo.!'! Clearly, more clinical studies need to be conducted to resolve this conflict.
Magnesium. Extracellular magnesium plays an important role in maintaining membrane polarization. Through its effect on calcium channels, magnesium can reduce the influx of calcium that leads to cell damage.'!"!" In the central nervous system, magnesium blocks the calciumdependent release of glutamate!'? and postsynaptically blocks NMDA receptors." Moreover, extracellular magnesium can improve inner ear rnicrocirculation.!" Because magnesium concentration in the perilymph decreases significantly after intense noise exposure.!" researchers have studied its protective effects in preventing noise-induced hearing loss. For example, Attias et al conducted a double-blind, placebo-controlled study and found that a group of patients who had been given oral magnesium supplements displayed a significantly lower incidence of noise-induced permanent threshold shifts than did the controls. 120 No significant side effects were identified.
In 1998, a highly motivated patient of the lead author elected to undergo catheter-delivered magnesium sulfate infusion to the round window. She had had right-sided tinnitus for 10 years, and it had become worse after she attended a football game 2 years earlier. Her tinnitus was severe and had not responded to aggressive medical intervention, including counseling, anxiolytic and oral steroid treatment, masking, and tinnitus retraining therapy. Within 60 seconds of the infusion of a dilute solution of magnesium sulfate via the round window microcatheter, the patient reported a complete resolution of her tinnitus. This effect persisted until the flow of solution was discontinued 48 hours later; at that point, her tinnitus returned within minutes.
Calpains
The calpains are a family of calcium-activated, neutral cysteine proteases. The two most common isozymesmu-calpain (calpain I) and m-calpain (calpain H)-are ubiquitously distributed throughout the body. The mucalpain is activated by micromolar concentrations (l to 20 /-1M) of intracellular Ca' "; the m-calpain is activated at higher concentrations (250 to 750 /-1M) of this ion.
Structurally, calpain contains a large calcium-dependent catalytic subunit (80 kD) and a smaller regulatory subunit (30 kD). The catalytic subunit contains four complexes that can bind to calcium. Calpain exhibits relative selectivity for proteolysis of a subset of cellular proteins. Normal substrates of calpain include cytoskele-Volume 82, Number 4 tal proteins, membrane proteins, transcription factors , calmodulin-binding proteins, and enzymes that are involved in signal transduction.P' i!" Because some of the most preferred substrates are structural proteins, it has been hypothesized that extensive calpain activity can lead to a loss of structural and membrane integrity, reducing the cells' ability to maintain homeostasis.
Although much is known about the structural and enzymologic properties of mu-calpain and m-calpain, information on their physiologic roles is limited. The major technical obstacle to calpain research is the difficulty in identifying the physiologically relevant substrates from among the tens of thousands of proteins in cells and the lack of sensitivity and specificity in detecting the in vivo proteolysis of these substrates in spatial terms. However, the physiologic and pathologic roles of cal pain have been implied by several investigators.P'''" Previous studies have shown that calpains playa harmful role in a variety of pathologic states. Calpain is believed to be strongly related to certain brain pathologies (e.g., ischemia,125,126 traumatic brain injury.F' and Alzheimer's disease!"), multiple sclerosis, 128toxic and anoxic injury to hepatocytes.!" oxidative stress in endothelial cells, "? spinal cord injury,131 human renal cell carcinoma.!" and calpain-mediated apoptosis.!" Several calpain antagonists are neuroprotective in vitro and in vivo during ischemia and in brain , spinal cord, and peripheral nerve injury . [134] [135] [136] Two studies showed that the oral administratiori of leupeptin, a potent calpain inhibitor, promoted neuronal muscle recovery after median nerve transection and repair. 137 ,138 Moreover, prolonged administration of leupeptin did not cause any adverse reactions. Immunofluorescent staining and Western blot analysis revealed that the continuous deli very ofieupeptin directly into the inner ear significantly reduced the amount of hearing loss experienced by chinchillas who had been exposed to noise. Calpains have been identified in the cochlea, and they are active during ischemic injury to cochlear tissues 139 and during noise-induced hearing loss. 140 Calpain inhibitors have been shown to significantly protect spiral ganglion neurons from damage by hypoxia and neurotrophin-withdrawal-induced apoptosis.!" Salvi et al showed that leupeptin caused as much as a 60% reduction in outer hair cell loss from acoustic overstimulation (an octave-band noise centered at 4.0 kHz for 48 hr) and significantly reduced the amount of hearing loss during recovery." In addition, no deleterious effects on auditory function as measured by auditory brainstemevoked response testing were observed when leupeptin was continuously administered for 4 days to the scala tympani of chinchillas.s'v" In an animal study at the lead author's institution, we found that I mg/ml of leupeptin could be safely infused into the round window membrane for 8 weeks.!" Leupeptin had no effect on cochlear Long-term studies have sugges ted that leupept in is safe when administered to primates orally or via intramuscular injection; toxicologic testing has indicated that it does not adverse ly effect hematology, clotting, or plasma complement component C3 profiles over a 6-month period. 125.140 Colle ctively, these data might provide the basis for future leupeptin clinical trials aimed at achievi ng tinnitu s control and preventing noise-induc ed hearing loss. The use of leupeptin to treat tinnitu s and noise-indu ced hearin g loss has not yet been attempted in humans.
Antioxidants
The primary function of antioxidants is to scavenge ROS and thus reduce the toxic effects of oxygen. ROS contain an unpaired number of electron s, which makes them chemically reactive and extremely toxic to subcellular and cellul ar structures . It has been speculated that ROS are invol ved in more than 100 clinical conditions.!" The y are produ ced in vivo durin g mitochondrial respiration as well as by auto-oxidation of chemical and biolo gic molecules. ROS are also enviro nmental contaminants and can be formed by ionizin g and ultraviolet radi ation. Typically, the effects of these molecules and their activation is deleteriou s to the cell and tissue involved. Some of these molecules have the ability to upregulate adhesion receptors, increa se vascular permeabilit y, damage DNA and tissues, impai r endotheli al function,6-l·142 and possibly contribute to hearin g loss, balance disturb ance , and tinnitus.
Many intrinsic enzymes protect cells from oxidativ e damage. They include superoxide dismutase,143glutathione peroxidase.!" glutathione transferase.!" and catal ase. Additionally, antioxidant mechani sms require the action of a variety of small molecules in the human diet, such as vitamin E (tocopherol) and vitamin C, which trap radical s in lipid-and water-soluble membr anes and reduce oxidative stress.':"
Experimentally and clin ically, it is well known that ROS are primarily generated as a byprodu ct of oxidative phosphorylation and ischemi a/reperfusion or prolonged hypoperfusion, as is seen in myocardial infarction , in cerebrovasc ular accidents, arid possibly in sudden sensorineural hearing loss. There is compelling evidence implicating ROS in the damage assoc iated with cochlear ischemia , noise traum a, and ototoxici ty. Specifically, localized inner ear ischemia and hypoxia (induced by selectively clamping the anteroinferior cerebellar artery) normally destroy the cochl ear action potenti al within seconds, and the effect becom es permanent after 8 minut es of ischemi a. Yet one study showe d that when rats were pretreated with allopurinol or superoxide dismutase/polyethylene glycol prior to the induction of ischemia, cochlear action potential thresholds were maintained." This Volume 82, Number 4 study was extended to eval uate noise-indu ced hearing loss, which has been shown to cause vascular perturbations. Subj ects that had been pretreated with scavenge rs and ROS blockers experienced less of a threshold shift than did controls (p<0.05).53
Amin oglycosides appear to cause their damage to the cochlea by generating ROS, which are generated after the antibiotic combines with iron to form an aminoglycoside/ iron complex. Sha and Schacht reported that iron-chelating agents were useful in attenuating amin oglycosideinduc ed cochlear damage. " Lautermann et al demonstrated a possible relationship between ototoxicity and dietary factor s.147Specifically, they showed that an ROS scavenger (glutathione) attenuated gentamicin-induced hearing loss in guine a pigs that had been placed on a lowprotein diet (as opposed to a regular diet). Other investigators have found similar mechanisms underlying ototoxicity seco ndary to other compound s. For example, Clerici et al showed that direct ROS-induc ed cochlear injur y followi ng cisplatin administration occurred in guinea pigs, but that ROS scave ngers afforded protection from cisplatin.148.149 They also demon strated that superox ide dismutase protects against trimethyltin chloride-induced ototoxicity.!"
The lead author's institution is also investigatin g the effects of glutathione (L-gamma-glutamyl-L-cysteinylglycine). Glutathione is an endogenous thiol-containing amino acid that detoxifies ROS. It is also involved in the metabolism and detoxification of xenobiotics, drug s, and drug metabolites, and it offers protection from oxidizing ROS via reactions catalyzed by glutathione S-transferase, transpeptidases, transhydrogenases, peroxidases, and reduct ases.P"!" Mitochondrial glutathione is critical to cell viability, and the glutathione redox cycle is a primary antioxidant defen se system within the mitochondrial matrix. '?
Many studies have demonstrated that high glutathione levels have a beneficial effect on cellular function, while low levels are harrnful.P"!" Specifically, it has been show n that sulfhydryl compounds limit gentamicininduced damage to outer hair cell s in vitro and that in vivo gentamicin ototoxicity can be dimini shed with glutath ione.159.160 Glutathione also offers protection from cisplatin ototoxicity.' ?' Conversely, systemic inhib ition of glutathione synthesis potenti ates the ototoxicity of the ethacrynic acid/kanamycincombination,162and glutathione depletion potentiates cisplatin nephrotoxicity.162·16-l It has also been shown that the toxicity of certain clinically used drugs occurs secondary to reduc ed glutathione level s and the assoc iated increase in ROS . 160.165-169 Other related studies have demon strated an 86% age-associated reduction in glutathione levels in the auditory nerve, while other cochl ear tissue s maintained stable levels." ?
Methionine
Methionine, a thio l-con taining esse ntia l amino acid, has metal-chelating!" and antioxidant properties.!" It has bee n shown that D-methionine suppresses gentamicininduced free-ra dica l for mation in vitro and in cell cultures.!" Furtherm ore, the concurrent systemic twice-daily administration of D-m ethi onine and gentamic in significantly attenuates aud itory threshold shifts in guinea pigs.!" Methionin e ca n also provide prote ction agai nst the ototoxic effects of cisplatin; D-methionine suppresses ci spl atin-induced dam age to auditor y hair cells in orga notypic cultu res.!" Other animal studies have revealed the protective effects of D-methi onine in preventing the hair cell loss and acute auditory threshold shifts induced by cisplatin adm inistration. 175, 176 Campbell et al reported that both D-m ethionine and the naturally occ urring L-methion ine , which is more eas ily metaboliz ed, co mpletely blocke d the ototoxic effec ts of cisplatin for 7 days in rats.!" Th e antineoplastic activity of cisplatin, however, was significa ntly reduced by D-and L-methionine, as assessed by in vitro cultures of tumor cell lines and tumors implanted in vivo.!" Conversely, a more recent study by Li et al showed that the administratio n of L-methionine to the round window memb rane of rats significan tly attenuated the ototox ic effects of cisplatin, as measured by auditory brainstem-evoked response testing, but did not interfere with the chemotherapeutic effectiveness of cisplatin in controlling a highly metastatic form of breast can cer.!" Among the many other age nts ava ilable to treat the inner ear are grape-seed extract (res veratrol) from red wine and pine-bark extract, both of which are excellent antioxidants. Preliminary studies in the lead author' s labor atory are in progress to help us underst and the effects of red-wine and grap e-seed extracts on noise-induced and age -related hearin g loss, Additionally, some nutriti onal supplements enhance mitochondrial function and energy output. One is a patented supplement that co ntains acetyl-L-carnitine, alpha lipoic acid, glutathione, and coenzyme Q-IO . In animal studies, these substances have been shown to protect aga inst age-related hearin g loss. 150 Perhaps direct perfusion of these substances to the inner ear will have an eve n more pronounced effect, but clearly additional studies are required .
T he ox idative stress th at is ca use d by hypoxia and ischemia produces a variety of damaging ROS , including hydrogen peroxide, the superox ide anion, and the hydroxyl radicaL53,54,56,57 The acc umulation of ROS , cytokines, and chemoki nes that is assoc iated with hypoxia and ischem ia prom otes the express ion of intercellular adhesio n molecul e-I (lCAM-I ) on endothelial cells, which subsequently leads to neutrophil-endothelial cell adhesion.v -" Thi s pro cess leads to an increase in circulating tissue levels of various cytokines.P' '!" leukotrienes,181 288 thromboxanes.'? platelet activa ting factor,' !' complement com ponents,184elastases, and other enzy mes, 185and it causes the formation of additional ROS. Typic ally, the effects of these molecules and their activation are deleterio us to the cells and tissues involved . Some of these substances upregulate leukocyte adhesion recept ors, increase vascular perm eabili ty, damage tissue s directly, impair endothelial function, and eve ntually lead to edem a, vasc ular insufficiency, and ultim ately necrosis.s' <'
Anti-ICAM-I antibody has been show n to attenuate damage in the brain , heart , kidney, and other tissues where ICAM-I plays a critical role in ischemia-induced damage.v -! " Studies have shown that ICAM-I also play s an important role in middle ear diseases (including otiti s media186-189and chole steatoma' i"!" ), inner ear inflammation ,192,193and carcinoma of the head and neck .'?' The lead author was involved in a recent study that assessed the possible protective effect of anti-ICAM-I antibody again st noise-induced cochl ear damage by eva luating noiseinduced temp orary threshold shifts.!" Ou r premi se was that intense noise exposure reduces coc hlear blood flow and causes ischemia, which leads to the production of ROS . The accumulation of ROS then promotes the expression of ICAM-I and initiates a cascade of event s that ultim ately leads to cochlear damage. Audi tory brainstemevo ked response testin g indicated that noise-induced temporary threshold shifts co uld be significantly attenu ated by administering anti-ICAM-I antibody intravenously. Thi s protective effect sugges ts that there is a mecha nism of inflammatory prevention whereby anti-ICAM-I antibody prevents ICAM-I fro m eliciting a deleterious response that would oth erwi se lead to cochlear dam age.
A significant amount of data shows that ROS promote the expression ofICAM-I on endothelial cells and subsequently on neutrophil-endothelial cell adhesion. 6l ,62, 196, 197 For example, hydrogen peroxide-induced polymorphonuclear neutrophil adhesion is dependent on the rapid indu ction of the ICAM-I mRNA signal and the surface ex press ion of ICAM-I on the endothelial cell . Everything you need to insert vent tubes .....
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Neurotrophic factors
Among the many causes of sensorineural hearing loss are noise trauma, aging, ototoxicity, and genetic, vascular, and viral influences. Ultimately, the damage caused by these processes leads to a uniform degeneration of hair cells, auditory neurons, or the VIIIth cranial nerve. Endogenous factors-including epidermal growth factor , transforming growth factor alpha, insulin, insulin-like growth factor-I, insulin-like growth factor-2, and glial cell-linederived neurotrophic factor (GDNF)-have been shown to play roles in the renewal and repair of damaged populations of hair cells in the mammalian labyrinth.198-2oo In mammals, this process seems to be limited to the vestibule, where supporting cells transdifferentiate into hair cells and/or damaged hair cells are repaired.P? By enhancing these endogenous protective mechanisms, potential therapeutic options for hearing loss might be revealed. Gao reported a study in which exogenous neurotrophic factors were applied to postnatal rat cochlear explant cultures that had been exposed to different classes of ototoxins; neurotrophin-4/5, brain-derived neurotrophic factor (BDNF), and neurotrophin-3 were found to protect spiral ganglion neurons from ototoxicity induced by gentamicin, sodium salicylate, and cisplatin''" Moreover, Gao found that concanavalin A, a lectin molecule, also significantly protected hair cells from gentamicin ototoxicity . In another study, Altschuler et al found that BDNF and GDNF enhanced spiral ganglion cell survival, while a combination of BDNF and fibroblast growth factor , induced peripheral process regrowth.i'" Others have shown that chronic infusion of both neurotrophin-3 and GDNF into the inner ear provided significant protection from acoustic trauma in guinea pigs. 203. 204 Staecker et al reported (1) that direct infusion of either neurotrophin-3 or BDNF into the scala tympani of a guinea pig cochlea after a loss of auditory hair cells compensates for the loss of trophic support (i.e., the inner hair cells), (2) that the infused neurotrophin protects the auditory neurons of the spiral ganglion from cell death induced by neurotrophin molecule withdrawal, and (3) that either BDNF or neurotrophin-3 stimulated neuritic overgrowth of the VIIIth cranial nerve peripheral processes.?" In an in vivo gene therapy study, Staecker et al introduced the gene for BDNF into the cochleae of mice that had neomycin-induced cochlear damage via the replication-defective HSVbdnflac viral vector. P" This BDNF gene therapy in the cochlea resulted in the preven-290 tion of the cochlear neuronal degeneration that was observed in the controls.
Many other gene-altering protective opportunities exist to repair defective or malfunctioning cells, including the use of other gene vectors and antisense oligonucleotides. Antisense oligonucleotides are small sect ions of synthesized cDNA (20 to 25 base pairs in length) that are complementary to a sequence of base pairs that are present .in the mRNA of the gene that is targeted for disruption . The antisense oligonucleotide binds to the mRNA and causes enzymes in the cell to degrade it, thereby effectively preventing translation of the targeted gene . Antisense oligonucleotides were shown to be effective in vitro for targeting molecules in the cell-death pathway (e.g ., c-Jun) in dissociated cell cultures of the rat spiral ganglion that had been exposed to oxidative stress with cisplatin.?" It is feasible that the infusion of antisense oligonucleotides targeted to certain genes in a cell-death signal pathway might also be effective in vivo because infused antisense oligonucleotides targeted to the GluR2 AMPA receptor have been shown to modify synaptic excitatory transmission in the cochleae of guinea pigs ."
Conclusion
Our management of inner ear diseases is limited only by our current lack of a full understanding of their pathophysiology. Once a mechanism has been elucidated, novel compounds or existing medications might prove to playa critical role in the management of an array of otologic symptoms and disorders .
It is important to remember that the types of treatments discussed in this article presume end-organ dysfunction . Although many otopathologies are end-organ in etiology, it is possible that many forms of tinnitus, for example, are centrally mediated and might not respond to local therapy at the inner ear. If central tinnitus represents overexcitation or overstimulation because of a loss of inhibition, it might be possible to precisely determine its site of origin by functional magnetic resonance imaging, single-photon emission computed tomography, positron-emission tomography, or other imaging modalities. It might then be possible to temporarily inhibit the precise area in the brain and alleviate the tinnitus through electrical stimulation or deafferentation with lidocaine. Provided that no adverse sequelae occur (i.e. , an expressive or receptive aphasia or the loss of an important auditory memory), this defined microarea of the brain could be ablated by either excision or cryotherapy, which might even result in a complete cure for some forms of tinnitus . From a more global perspective, the utility of pharmacologic manipulation of the membranous labyrinth might playa considerable role in the treatment of a variety of otologic disorders.
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